Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Proteonova Inc. maintains a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. Currently, there is 1 pending office action within the portfolio. This action is situated in 1 distinct art unit, which shows that the company's current patenting activity is concentrated within a specific technical division of the patent office.
The prosecution of this matter is handled by 1 distinct examiner, FLINDERS, JEREMY C. As the busiest examiner for the portfolio, FLINDERS, JEREMY C is responsible for 1 busiest examiner pending office action. This 1 pending action is the only active matter for Proteonova Inc., indicating a focused prosecution strategy at this time.
For practitioners, the presence of 1 pending office action and 1 distinct examiner in 1 distinct art unit allows for a singular focus. The strategy can be specifically tailored to the preferences of FLINDERS, JEREMY C. Since the workload is confined to the Biotechnology & Pharmaceuticals technology area and a single examiner, the firm can efficiently manage the 1 pending office action by focusing on the specific procedural expectations of that examiner.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| FLINDERS, JEREMY C | 1 | 63.5% | +16.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18306189 | MODULAR TARGETED THERAPEUTIC AGENTS AND METHODS OF MAKING SAME | FLINDERS, JEREMY C | — |
| Art Unit | Apps |
|---|---|
| 1684 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18306189 | MODULAR TARGETED THERAPEUTIC AGENTS AND METHODS OF MAKING SAME | FLINDERS, JEREMY C | 1684 | §102§112DP | Non-Final OA | — | Pending | Apr 24, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial